Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not ...

The Defence Research and Development Laboratory (DRDL), Hyderabad is a premier laboratory of the Defence Research and ...

Fingal County Council has declared a planning application by the National Transport Authority for a ‘strategic’ park-and-ride ...

DHAKA, July 15, 2025 (BSS) - The Ministry of Religious Affairs has sought application from authorized agencies to participate ...

Candidates are advised to apply well before the deadline and carefully follow all application instructions, as incomplete or ...

West Bengal Leader of Opposition Suvendu Adhikari on Monday said that he has written to the Chief Election Commissioner of In ...

Replimune, which was seeking approval of RP1 in combination with Bristol Myers Squibb's Opdivo for the treatment of advanced melanoma, on Tuesday said the FDA issued a so-called complete response ...

So, here are six tell-tale ways to make sure recruiters know (or at least think) your grad job application was actually ...

Shares fell 75% to $3.04, putting the stock on track for a record closing low, according to Dow Jones Market Data. The stock ...

Capricor Therapeutics (CAPR) shares fell Friday after the company announced it received a complete response letter from the FDA for its Biologics License Application for Deramiocel.

The US Food and Drug Administration (FDA) has announced the publication of more than 200 complete response letters (CRLs), ...